VXRT Vaxart

Vaxart, Inc. to Participate in September Virtual Investor Conferences

Vaxart, Inc. to Participate in September Virtual Investor Conferences

- H.C. Wainwright: 22nd Annual Global Investment Conference - September 14th – 16th

- Sachs Associates: 20th Annual Biotech in Europe Forum - September 21st – 24th

- SVB Leerink: CybeRx Series: Vaccine Forum - September 23rd & – 24th

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced senior management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:

H.C. Wainwright: 22nd Annual Global Investment Conference

Title:Vaxart, Inc. (VXRT) Company Presentation / Fireside Chat
Date:Monday, September 14th 2020
Time:10:30 am Eastern Time
Presenter:Andrei Floroiu, President & CEO
  
Sachs Associates: 20th Annual Biotech in Europe Forum
Title (1):Pandemic Response Day: Vaccine Panel
Date:Monday, September 21st 2020
Time:13:05 -14:00 Central European Time
Panelists:Andrei Floroiu, President & CEO Vaxart, Inc.

 Andrew Allen, Co-Founder, President & CEO, Gritstone Oncology
 Frederic Ors, CEO, IMV, Inc.
 Johan Van Hoof, Global Therapeutic Area Head, IDV Vaccines, Johnson & Johnson
  
Title (2):Spotlight Showcase Vaxart, Inc. (VXRT) Company Presentation
Date:Monday, September 21st 2020
Time:14:05 -14:25 Central European Time
Presenter:Andrei Floroiu, President & CEO Vaxart, Inc.
  
SVB LEERINK: CybeRx Series – Vaccine Forum
Title:Vaxart, Inc. (VXRT) - Fireside Chat
Date:Wednesday, September 23rd 2020
Time:2:00 am Eastern Time
Presenters:Andrei Floroiu, President & CEO
 Sean Tucker, Ph.D., Founder & Chief Scientific Officer

Webcast Links

A link to the webcasts along with a replay of the webcasts will be accessible on the Events & Presentations page of the Investors section on the Company’s website.

About Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and has the potential to provide sterilizing immunity for diseases such as COVID-19. Vaxart believes that a room temperature stable tablet vaccine is easier to distribute, store and administer than injectable vaccines and may provide significantly faster response to a pandemic than injectable vaccines, enabling a greater portion of the population to be protected. Vaxart’s development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). For more information, please visit

Contacts

Investors:

Joyce Allaire

LifeSci Advisors



617.435.6602

Media:

Gloria Gasaatura

LifeSci Communications



646.970.4688

EN
03/09/2020

Underlying

VXRTVaxart

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaxart

 PRESS RELEASE
Free
VXRT VAXART

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Preliminary results from the Annual Meeting indicate that two proposals were approved and two proposals were rejected by Vaxart stockholders. Stockholders voted in favor of...

June 13, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Ge...

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology - Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation constructs, supporting potential for improved protection against infection - - Vaccine candidates were safe and well-tolerated across all dose groups with no vaccine-related serious adverse events reported - - Conference call...

June 11, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Top...

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time t...

June 10, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Vaxart Announces Adjournment of Annual Meeting of Stockholders Meeting adjourned to June 13, 2025 at 8:30 a.m. Pacific Time Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 12, 2025 Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”) announced today that its 2025 annual meeting of stockholders (the “Annual Meeting”) has been adjourned to Friday, June 13, 2025...

June 2, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Participate at the Jefferies Global Healthcare Conference on...

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00 PM ET. A live webcast of the fireside chat will be available on the Company’s website at or by . A replay of the...

May 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch